Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE1A | P54750 | 1/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zagociguat SCHEMBL19922804 | 0.97 | AR (0.34) | PDE5APDE4APDE1APDE1BPDE4B | |
| Zagociguat SCHEMBL21332996 | 0.96 | AR (0.34) | PDE5APDE4APDE1APDE1BPDE4B | |
| Zagociguat SCHEMBL21333483 | 0.94 | PDE5A (0.35) | PDE5APDE4APDE1APDE1BPDE4B | |
| Zagociguat SCHEMBL21332766 | 0.93 | PDE5A (0.34) | PDE5APDE4APDE1APDE1BPDE4B | |
| Zagociguat SCHEMBL21332705 | 0.92 | PDE5A (0.33) | PDE5APDE4APDE1APDE1BPDE4B | |
| SCHEMBL19922726 | 0.90 | EPHB4 (0.32) | — | |
| SCHEMBL19922775 | 0.90 | AR (0.33) | ARKDM4EALDH1A1TP53SMN1; SMN2 | |
| Zagociguat SCHEMBL21333489 | 0.89 | MEN1 (0.33) | PDE5APDE4APDE1APDE1BPDE4B | |
| SCHEMBL26415379 | 0.87 | AR (0.34) | ARKDM4EALDH1A1TP53SMN1; SMN2 | |
| Zagociguat SCHEMBL21332823 | 0.86 | EPHB4 (0.32) | PDE5APDE4APDE1APDE1BPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3762389-B1 | CRYSTALLINE FORMS OF AN SGC STIMULATOR | TISENTO THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230095799-A1 | CRYSTALLINE FORMS OF AN sGC STIMULATOR | TISENTO THERAPEUTICS INC. | 2023-03-30 | — | — | US | disclosed |
| US-20210115050-A1 | CRYSTALLINE FORMS OF AN sGC STIMULATOR | TISENTO THERAPEUTICS INC. | 2021-04-22 | — | — | US | disclosed |
| EP-3762389-A1 | CRYSTALLINE FORMS OF AN SGC STIMULATOR | Cyclerion Therapeutics, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| WO-2019173551-A1 | CRYSTALLINE FORMS OF AN SGC STIMULATOR | CYCLERION THERAPEUTICS, INC. (US) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115050-A1 | CRYSTALLINE FORMS OF AN sGC STIMULATOR | GUCY1A2, GUCY1B2, GUCY1A1 | PDE5A 8/4885PDE4A 16/4885PDE1A 39/4885 |
| US-20230095799-A1 | CRYSTALLINE FORMS OF AN sGC STIMULATOR | GUCY1A2, GUCY1B2, GUCY1A1 | PDE5A 8/4885PDE4A 16/4885PDE1A 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.